Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug Posted byZacks Equity Research January 11, 2022 Leave a comment on Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.